An observational study into the usage and efficacy of Crestor [rosuvastatin] 5mg as a start dosage in achieving the LDL-C [low-density lipoprotein cholesterol] target level in both statin-naive and treated primary and secondary prevention patients with a high risk of a cardiovascular event.

Trial Profile

An observational study into the usage and efficacy of Crestor [rosuvastatin] 5mg as a start dosage in achieving the LDL-C [low-density lipoprotein cholesterol] target level in both statin-naive and treated primary and secondary prevention patients with a high risk of a cardiovascular event.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2011

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms OPTIMAL
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Feb 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
    • 26 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top